Becton Dickinson's rapid flu test:
This article was originally published in Clinica
Becton Dickinson has received US FDA 510(k) clearance for Directigen EZ Flu A+B, a two-step, easy-to-read test that can clearly differentiate between influenza A and influenza B in 15 minutes or less. A confirmed differential diagnosis helps guide healthcare providers in the selection of appropriate treatment, such as administration of antivirals to certain patient populations, the company said, noting that analytical studies have shown that the test can also detect avian influenza H5N1 isolates.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.